Stricken language would be deleted from and underlined language would be added to the law as it existed prior to this session of the General Assembly.

1	State of Arkansas	As Engrossed: S2/26/01		
2	83rd General Assembly	A Bill		
3	Regular Session, 2001	SI	ENATE BILL	339
4				
5	By: Senator P. Malone			
6				
7				
8		For An Act To Be Entitled		
9	AN ACT	TO AMEND VARIOUS SECTIONS OF THE PHARMACY AC	CT,	
10	ARKANSA	S CODE 17-92-101 THROUGH 17-92-909; TO		
11	AUTHORI	ZE MEMBERS OF THE BOARD OF PHARMACY TO ISSUE	Ε	
12	TEMPORA	RY PRACTICE PERMITS TO PHARMACISTS LICENSED	IN	
13	OTHER S	TATES; TO ALLOW ISSUANCE OF LICENSES IN DISE	EASE	
14	STATE M	ANAGEMENT BY AGENCIES APPROVED BY THE ARKANS	SAS	
15	STATE B	OARD OF PHARMACY; TO PROVIDE PHARMACISTS WIT	ТН	
16	GREATER	FLEXIBILITY REGARDING THE DISPENSING OF		
17	GENERI C	DRUGS AND PRICE GUIDELINES FOR GENERIC DRUG	GS;	
18	AND FOR	OTHER PURPOSES.		
19				
20		Subtitle		
21	AN	ACT TO AMEND VARIOUS SECTIONS OF THE		
22	PH	IARMACY ACT, ARKANSAS CODE 17-92-101		
23	TH	IROUGH 17-92-909.		
24				
25				
26	BE IT ENACTED BY TH	E GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:	:	
27				
28	SECTION 1. Ar	kansas Code 17-92-101 is amended to read as	follows:	
29	17-92-101. De	fi ni ti ons.		
30	As used in th	is chapter, unless the context otherwise red	qui res:	
31	(1) "B	oard of Pharmacy" means the Arkansas State E	Board of	
32	Pharmacy;			
33	(2) "C	redentialing" means the issuance <u>of or appro</u>	oval by the	
34	Arkansas State Boar	d of Pharmacy of a credential <u>, issued to a p</u>	pharmacist b	y ar
35	agency approved by	the board, certifying that the pharmacist ha	as met the	
36	standards of compet	ency established by the board for disease s	tate managem	ent

CPB059

1 or other pharmacy services necessitating a credential;

4 5

6

7

13

14 15

16

26

27

28

29

33

2 (3) "Dentist" means a practitioner of dentistry duly licensed under the laws of this or some other state; 3

- (4)(A) "Disease state management" means a strategy which utilizes a team-oriented, multidisciplinary approach to improve health care outcomes and quality of care, and when possible, to control health care cost through management of targeted chronic disease states.
- (B) Disease state management focuses on improving health 8 9 care from prevention to diagnosis and treatment to on-going follow-up.
- 10 (C) Disease state management will involve, but not be 11 limited to, patient education and self-care techniques and out-patient drug 12 therapy management pursuant to a patient care plan;
 - (5) "Drug" shall include all medicines and preparations recognized in the United States Pharmacopoeia or the National Formulary for substances intended to be used for the care, mitigation, or prevention of disease of either man or other animal;
- 17 (6) "Generically equivalent" means a drug that is 18 pharmaceutically equivalent and therapeutically equivalent to the drug 19 prescri bed;
- 20 (6) (7) "Licensed pharmacist" means a person holding a license 21 under the provisions of this chapter;
- 22 $\frac{7}{8}$ "Medicine" means a drug or preparation of drugs in 23 suitable form for use as a curative or remedial substance;
- 24 (8) (9) "Optometrist" means a practitioner of optometry duly 25 licensed under the laws of this state;
 - $\frac{(9)}{(10)}$ "Patient care plan" means a written course of action which is patient or physician or pharmacist specific and disease specific for helping a patient to achieve outcomes that improve a patient's quality of Li fe:
- 30 (10)(11) "Pharmacy" means the place licensed by the board in 31 which drugs, chemicals, medicines, prescriptions, and poisons are compounded, 32 dispensed, or sold at retail;
- (11)(12) "Pharmacy care" means the process by which a pharmacist in consultation with the prescribing practitioner identifies, resolves, and 34 35 prevents potential and actual drug-related problems and optimizes patient therapy outcomes through the responsible provision of drug therapy or disease 36

1 state management for the purpose of achieving any of the following definite 2 outcomes that improve a patient's quality of life: 3 (A) Cure of di sease; 4 (B) Elimination or reduction of a patient's symptomology; 5 (C) Arresting or slowing a disease process; or (D) Preventing a disease or symptomology; 6 7 (13) "Pharmaceutically equivalent" means drug products that have 8 identical amounts of the same active chemical ingredients in the same dosage 9 form and that meet the identical compendial or other applicable standards of strength quality, and purity according to the United States Pharmacopoeia or 10 11 another nationally recognized compendium; (12)(14) "Physician" means a practitioner of medicine duly 12 13 licensed under the laws of this or some other state: 14 (13)(15) "Poi sons" means any drug, chemical, medicine, or preparation liable to be destructive to adult human life in quantities of 15 16 sixty (60) grains or less; 17 (14)(16) (A) "Practice of pharmacy" means the learned profession 18 of: 19 (i) Dispensing, selling, distributing, transferring 20 possession of, vending, bartering, or in accordance with regulations adopted 21 by the board, administering drugs, medicines, poisons, or chemicals which, 22 under the laws of the United States or the State of Arkansas, may be sold or dispensed only on the prescription and order of a practitioner authorized by 23 24 law to prescribe drugs, medicines, poisons, or chemicals. Except in accordance 25 with regulations adopted by the board as recommended by the Medications 26 Administration Advisory Committee, the administration of medications shall be limited to the following classifications of medications: immunizations, 27 28 vaccines, allergy medications, vitamins, minerals, antihyperglycemics, and 29 antinausea medications. The administration of medications shall not include 30 the administration of medications to any person under the age of eighteen 31 (18);32 (ii) Placing, packing, pouring, or putting in a 33 container for dispensing, sale, distribution, transfer possession of, vending, or bartering any drug, medicine, poison, or chemical which, under the laws of 34 35 the United States or the State of Arkansas, may be sold or dispensed only on the prescription of a practitioner authorized by law to prescribe drugs, 36

1 medicines, poisons, or chemicals; 2 (iii) Placing in or affixing upon any container 3 described in subdivision (14)(A)(ii) of this section a label required to be 4 placed upon drugs, medicines, poisons, or chemicals sold or dispensed upon prescription of a practitioner authorized by law to prescribe those drugs, 5 6 medicines, poisons, or chemicals; 7 (iv) Preparing, typing, or writing labels to be placed in or affixed on any container described in subdivision (14)(A)(ii) of 8 9 this section, which label is required to be placed upon drugs, medicines, poisons, or chemicals sold or dispensed upon prescription of a practitioner 10 11 authorized by law to prescribe those drugs, medicines, poisons, or chemicals; (v) Interpreting prescriptions for drugs, medicines, 12 13 poisons, or chemicals issued by practitioners authorized by law to prescribe drugs, medicines, poisons, or chemicals which may be sold or dispensed only on 14 15 prescri pti on; 16 (vi) Selecting, taking from, and replacing upon 17 shelves in the prescription department of a pharmacy or apothecary drugs, medicines, chemicals, or poisons which are required by the law of the United 18 19 States or the State of Arkansas to be sold or dispensed only on prescription 20 of a practitioner authorized by law to prescribe them; 21 (vii) Compounding, mixing, preparing, or combining 22 drugs, medicines, chemicals, or poisons which, under the laws of the United States or the State of Arkansas, may be sold or dispensed only on the 23 24 prescription of a practitioner authorized by law to prescribe them; 25 (viii) Advising and providing information concerning 26 utilization of drugs and devices and participation in drug utilization 27 revi ews; 28 (ix)(a) Performing a specific act of drug therapy 29 management or disease state management delegated to a pharmacist for an 30 individual patient based upon a written protocol or a patient care plan 31 approved by the patient's physician, who shall be licensed in this state under 32 the Arkansas Medical Practices Act, § 17-95-201 et seg. 33 (b) Drug therapy management shall not include the selection of drug products not prescribed by the physician, unless the 34 35 drug products are either named in the physician-initiated protocol or the physician-approved patient care plan; 36

1	(x) Provi di ng pharmacy care; and
2	(xi) Providing pharmacokenetic services.
3	(B) The provisions of subdivisions (14)(A) and (C) of this
4	section shall not apply to employees of wholesale drug companies or other drug
5	distributors who do not fill prescriptions or sell or dispense drugs to the
6	consumer.
7	(C)(i) The board may permit pharmacy technicians other than
8	pharmacists or interns to perform some or all of those functions described in
9	board regulations under the direct, personal supervision of a licensed
10	pharmacist pursuant to regulations defining the minimum qualifications of such
11	employees, the ratio of pharmacy technicians to supervising pharmacists and
12	the scope of the duties, practices, and procedures which the board determines
13	will promote the delivery of competent, professional pharmaceutical services
14	and promote the public health and welfare. Nothing in this chapter shall be
15	construed as allowing pharmacy technicians to administer medications.
16	(ii) The conduct of a pharmacy technician is the
17	responsibility of the pharmacist-in-charge and supervising pharmacist of the
18	pharmacy who shall not permit the employee to perform any act, task, or
19	function which involves the exercise of independent judgment by the employee.
20	(iii) Pharmacy products prepared by pharmacy
21	technicians shall be verified for accuracy by the supervising pharmacist prior
22	to release for patient use, and the verification shall be documented.
23	(iv) The use of pharmacy technicians in a manner not
24	authorized by this chapter or regulations promulgated hereunder shall be
25	unprofessional conduct by the pharmacist-in-charge and the supervising
26	pharmacist.
27	(v) It is recognized that hospital pharmacy
28	technicians as defined in § 17-92-602(5) are governed by the Hospital
29	Pharmacies Act, § 17-92-601 et seq., and related board regulations developed
30	pursuant to that subchapter;
31	(15)(17) "Prescription" means an order for medicine or medicines
32	usually written as a formula by a physician, optometrist, dentist,
33	veterinarian, or other licensed medicinal practitioner. It contains the names
34	and quantities of the desired substance, with instructions to the pharmacist
35	for its preparation and to the patient for the use of the medicine at a
36	particular time;

1	(16)(18) "Proprietary medicines", when not otherwise limited,
2	means remedies that a certain individual or individuals have the exclusive
3	right to manufacture or sell;
4	(17)(19) "Supervision" means under the direct charge or direction
5	and does not contemplate any continued absence of such supervision;
6	(20) "Therapeutically equivalent" means pharmaceutically
7	equivalent drug products that, if administered in the same amounts, will
8	provide the same therapeutic effect, identical in duration and intensity;
9	(18)(21) "Veterinarian" means a practitioner of veterinary
10	medicine duly licensed under the laws of this or some other state; and
11	(19)(22) (A) "Written protocol" means a physician's order,
12	standing medical order, standing delegation order, or other order or protocol
13	as defined by regulation of the Arkansas State Medical Board under the
14	Arkansas Medical Practices Act, § 17-95-201 et seq.
15	(B) Except for immunizations and vaccinations, which may be
16	general protocols, protocols shall be patient or physician or pharmacist
17	specific for prescriptions or orders given by the physician authorizing the
18	protocol.
19	
20	SECTION 2. Arkansas Code 17-92-308, regarding reciprocity for
21	pharmacists licensed in other states, is amended by adding the following
22	additional subsection:
23	(c)(1) In the interim between sessions of the board and upon
24	satisfactory evidence of the fitness, as established by board regulation, of
25	an applicant for reciprocity, any member of the board, in his or her
26	discretion, may issue a temporary certificate which shall authorize the holder
27	to practice pharmacy as set forth in Section 17-92-101.
28	(2) The temporary certificate shall expire on the date of the
29	next meeting of the board after the granting of the certificate, whether that
30	meeting is a regular meeting or a called meeting at which reciprocity is
31	consi dered.
32	
33	SECTION 3. Arkansas Code 17-92-316 is amended to read as follows:
34	17-92-316. Credential required for professional pharmacy service.
35	(a) The Arkansas State Board of Pharmacy shall issue a credential in
36	disease state management, or any other pharmacy service that necessitates a

1 credential, as defined by board regulations, if the candidate meets the 2 competencies, standards, and objectives defined by the board's regulations. (a)(1) The Arkansas State Board of Pharmacy may provide by regulation 3 4 for credentialing and approval of pharmacists to practice disease state 5 management and any other pharmacy services determined by the board to require 6 a credential. 7 (2)(A) The credentials may be issued by agencies approved by the 8 board to pharmacists who qualify pursuant to minimum competencies, standards, 9 objectives, and qualifications determined by the board. 10 (B) However, a credential shall not authorize the 11 pharmacist to practice the credentialed pharmacy service in Arkansas until after the board has determined that the credentialed pharmacist meets the 12 13 above minimum competencies, standards, objectives, and qualifications determined by the board. 14 15 (b) A pharmacist who holds any credential issued under subsection (a) 16 of this section shall renew the credential annually. 17 (b) The board shall adopt regulations necessary and appropriate to implement the credentialing and the board's approval of pharmacists to 18 19 practice disease state management and other credentialed pharmacy services, 20 i ncl udi ng: 21 (1) Identification of areas of credentialed pharmacy services; 22 (2) Identification of the minimum competencies, standards, 23 objectives, and qualifications necessary for a credential and the board's 24 approval to practice in each area of credentialed pharmacy service; 25 (3) Identification of the standards for qualifying an agency to 26 issue credentials for areas of pharmacy services; 27 (4) The procedure and standards, which may include a practical 28 examination, for the board's review and approval of a credential and 29 determination of a pharmacist's qualifications to practice disease state 30 management or other credentialed pharmacy service; 31 (5) The conversion of a credential previously issued by the board 32 for the practice of disease state management or other pharmacy service to a 33 credential issued by an approved credentialing agency; 34 (6) Continuing professional education and other measures to 35 maintain pharmacists' continuing competency in disease state management and 36 other credentialed pharmacy services.

1	(c)	The	board	shall	promul gate	regul ati ons	to:
	()	1110	Dodi u	Juli	promargate	1 cgai a ti ons	LO.

- 2 (1) Identify areas of credentialing;
 - (2) Establish procedures for initial application and renewal;
 - (3) Define the minimum competencies and standards to be examined;
 - (4) Define the qualifications for credentialing; and
 - (5) Define required continuing education, competencies, standards, and other information necessary to implement this chapter.

SECTION 4. Arkansas Code 17-92-503 is amended to read as follows:

10 17-92-503. Generic substitutions.

(a)(1) When a pharmacist receives a prescription for a brand or trade name drug product, the pharmacist may dispense, except as provided in subsection (b) of this section, a lower cost generically equivalent drug product unless such drug product appears on the nonequivalent drug product list as provided in § 17-92-504.

- (2) The total amount charged for the substituted generically equivalent drug product or for dispensing the drug product shall not exceed the amount normally and regularly charged under comparable circumstances by the pharmacist for that drug product or for the dispensing of that drug product.
- (3) A pharmacist may not dispense a drug product with a total charge that exceeds the total charge of the drug product originally prescribed unless agreed to by the purchaser.
- (b) The pharmacist shall not dispense a generically equivalent drug product under subsection (a) of this section if:
- (1) The prescriber, in the case of a prescription in writing signed by the prescriber, indicates in his own handwriting by name or initial that no substitution shall be made;
- (2) The prescriber, in the case of a prescription other than one in writing signed by the prescriber, expressly indicates the prescription is to be dispensed as communicated; or
- (3) The person for whom the drug product is prescribed indicates the prescription is to be dispensed as written or communicated—; or
- (4) The board has determined that the drug should not be substituted and has notified all pharmacists of that determination.

1 SECTION 5. Arkansas Code 17-92-503, regarding substitution of generic 2 for brand-name drugs, is amended by adding the following additional 3 subsection: 4 (c)(1) The Arkansas State Board of Pharmacy shall determine which drugs are generically equivalent as defined in this act, relying on standards 5 6 scientifically supported and generally accepted in the field of pharmacy, and 7 shall notify each licensed pharmacist and the Arkansas State Medical Board of 8 this determination. 9 (2) In making this determination, the Arkansas State Board of Pharmacy 10 may use a nationally recognized reference source that meets the requirements 11 of this act, notifying each licensed pharmacist and the Arkansas State Medical 12 Board of the reference source to be used and any additions or deletions the Board may make in its discretion. 13 14 15 SECTION 6. Arkansas Code 17-92-504 is repealed: 16 17-92-504. Nonequi val ent drug product list. (a)(1) The Arkansas State Board of Pharmacy shall be responsible for 17 18 determining and designating drug products which in its best judgment are not 19 equi val ent in quality and effectiveness and which, because of nonequival ency, would pose a substantial threat to the health, safety, and welfare of the 20 21 people of Arkansas if such drug products were subject to dispensing under the 22 provisions of § 17-92-503. 23 (2) The Arkansas State Board of Pharmacy shall promulgate a 24 nonequivalent drug product list of those drug products which it has determined 25 are not equivalent in quality and effectiveness. 26 (3) The Arkansas State Board of Pharmacy shall provide a copy of 27 the nonequivalent drug product list and changes to each pharmacist licensed with the Arkansas State Board of Pharmacy and to the Arkansas State Medical 28 29 Board. (b)(1) From time to time the Arkansas State Board of Pharmacy shall 30 31 make such additions to or deletions from the nonequivalent drug product list as it deems appropriate and in the best interest and for the health, safety, 32 33 and welfare of the people of this state. 34 (2) Notification of additions or deletions promptly shall be made 35 to each pharmacist Licensed with the Arkansas State Board of Pharmacy and to 36 the Arkansas Medical Board.

1	(c) No pharmacist may dispense a generically equivalent drug product as
2	provided in § 17-92-503 if the drug product appears on the current
3	nonequivalent drug product list as promulgated by the Arkansas State Board of
4	Pharmacy in accordance with subsection (d) of this section.
5	(d)(1) In determining and designating drug products which are not
6	equivalent in quality and effectiveness, including the promulgation of the
7	nonequivalent drug product list and additions and deletions thereto, the
8	Arkansas State Board of Pharmacy shall comply with the provisions of the
9	Arkansas Administrative Procedure Act, as amended, § 25-15-201 et seq.
10	(2) However, any opponent to the inclusion within, addition to,
11	or deletion from the nonequivalent drug product list of any drug product shall
12	have the burden of proof to show cause why the inclusion, addition, or
13	del eti on shoul d not be made.
14	/s/ P. Mal one
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	